Response Pharmaceuticals key facts
as of Oct 2026- Developer an intestinal microsomal triglyceride transfer protein inhibitor designed to treat the metabolic side effects of antipsychotic drugs.
- Response Pharmaceuticals is valued at approximately $30.0M as of Oct 2026, set at its early-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $16.9M across 2 recorded rounds; the latest was Debt ($3.9M) in Jun 2024.
- Notable investors include Evolution VC Partners, CrossWork, Collage Venture Partners, K2X, Momentum Biotech — 6 tracked in total.
- Response Pharmaceuticals has filed 3 Form Ds with the SEC since 2022, most recently Jun 2024 ($3.9M sold to 51 investors).
- Status: Privately Held (backing).
Valued at $30.0M at its early-stage round, Nov 2025. Nothing has traded since.
- ·Watch Response Pharmaceuticals: the Monday email on marks, rounds and moves
Response Pharmaceuticals funding rounds
2 roundsWho backs Response Pharmaceuticals
6Response Pharmaceuticals valuation
Response Pharmaceuticals was valued at $30 million at its early-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Response Pharmaceuticals raised?
Response Pharmaceuticals has raised $16.9 million in total; 2 of its rounds are on record. The largest on record was an $8 million early-stage round in Feb 2022; the most recent was a $3.9 million debt round in Jun 2024.
Response Pharmaceuticals has filed 3 Form Ds with the SEC since 2022, most recently in Jun 2024 ($3.9 million sold to 51 investors).
Response Pharmaceuticals investors
6 investors are on record for Response Pharmaceuticals, including Evolution VC Partners, CrossWork, Collage Venture Partners and K2X. The debt round in Jun 2024 drew 51 investors.
About Response Pharmaceuticals
Developer an intestinal microsomal triglyceride transfer protein inhibitor designed to treat the metabolic side effects of antipsychotic drugs. The company develops treatments for post-prandial triglyceride levels, body weight, and other cardiometabolic risk factors in individuals discontinuing semaglutide or tirzepatide, enabling patients to recover from mental illness and combat weight gain and metabolic dysregulation.
- Sector
- Healthcare
- HQ
- Falls Church, VA, United States
- Founded
- 2021
- Employees
- 10
- Website
- responsepharmaceuticals.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.